Treat-to-target bij SpA: wat als het doel is bereikt?

Bronnen:
Landewé R, Sieper J, Mease P, et al. Efficacy and safety of continuing versus withdrawing adalimumab (ADA) in maintaining remission in patients with non-radiographic axial spondyloarthritis (NR-AXSPA). EULAR 2018. Abstract OP0334.